Autosomal Dominant Polycystic Kidney Disease Clinical Landscape Report 2026: Trials, Readouts and White Space

Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.

Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.

Executive view

Autosomal Dominant Polycystic Kidney Disease remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 86 matched trial records and 128 indexed result records before the decision-focused sample below was selected.

How PatSnap MCP built this report

The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.

Trial landscape table

The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.

What indexed results say

• A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease (Phase 2/3): the indexed record reports Height-adjusted Total Liver Volume (htTLV)(Least Squares Mean) = 3.9 percentage (95% Confidence Interval, 0.1 - 7.7); Height-adjusted Total Liver Volume (htTLV)(Least Squares Mean): estimated relative treatment diff (%) = -4.3(95% CI, -8.4 to -0.1), P-Value = 0.0443; Height-adjusted Total Liver Volume (htTLV)(Least Squares Mean): estimated relative treatment diff (%) = -4.3(95% CI, -8.4 to -0.1), P-Value = 0.0443.
• Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD (Phase 1): the indexed record reports PC1 and PC2 = Increases in PC1 and PC2 were shown for 2, 3 mg/kg and 300 mg fixed doses versus placebo (p<0.05 for PC1 and PC2 for each dose).; PC1 and PC2 = Increases in PC1 and PC2 were shown for 2, 3 mg/kg and 300 mg fixed doses versus placebo (p<0.05 for PC1 and PC2 for each dose)..
• A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease (Phase 2): the indexed record reports HtTKV(annual change) = 3.1 % ( 1.4 - 6.8); HtTKV(annual change) = 4.3 % ( 3.0 - 6.6).

Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.

Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.

Asset and sponsor context

PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Rosuvastatin Calcium (Approved; HMGCR), Fluconazole (Approved; CYP51A1), Cyclosporine (Approved; CaN). Company & Deal Intelligence records identify sponsor context for Assaf Harofeh Medical Center, Jiangxi Jemincare Group Co., Ltd., Tokyo Women's Medical University Educational Association. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.

Where the white space is

1. Active-comparator trials on top of contemporary standard of care.
2. Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
3. Evidence in underrepresented populations and patients with multiple comorbidities.
4. Durability, adherence and post-discontinuation outcomes.

Strategic implications

For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.

What to monitor next

Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.

Bottom line

Autosomal Dominant Polycystic Kidney Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.